Erste Asset Management GmbH Buys 490,000 Shares of Replimune Group, Inc. $REPL

Erste Asset Management GmbH lifted its stake in Replimune Group, Inc. (NASDAQ:REPL) by 30.1% in the 4th quarter, HoldingsChannel reports. The fund owned 2,120,000 shares of the company’s stock after purchasing an additional 490,000 shares during the quarter. Erste Asset Management GmbH’s holdings in Replimune Group were worth $20,619,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. International Assets Investment Management LLC bought a new position in shares of Replimune Group in the 4th quarter worth $29,000. CWM LLC boosted its stake in Replimune Group by 248.6% in the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after acquiring an additional 1,879 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Replimune Group in the second quarter valued at approximately $69,000. Finally, Russell Investments Group Ltd. boosted its stake in Replimune Group by 3,638.9% in the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after acquiring an additional 7,569 shares in the last quarter. 92.53% of the stock is owned by institutional investors.

Replimune Group Trading Down 5.3%

NASDAQ REPL opened at $8.97 on Tuesday. The company has a fifty day simple moving average of $5.14 and a two-hundred day simple moving average of $7.27. The stock has a market cap of $740.65 million, a P/E ratio of -2.61 and a beta of 0.88. Replimune Group, Inc. has a 12-month low of $1.50 and a 12-month high of $13.24. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33.

Insider Activity

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the transaction, the insider owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

REPL has been the subject of several recent analyst reports. Cantor Fitzgerald downgraded shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Wedbush raised their target price on shares of Replimune Group from $2.00 to $6.00 and gave the company a “neutral” rating in a research note on Monday, June 1st. Jefferies Financial Group restated a “hold” rating and issued a $2.00 target price (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research note on Monday, April 13th. Finally, Leerink Partners restated a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Seven equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus target price of $4.88.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.